NASDAQ:EYEN - Eyenovia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.3225 -0.13 (-2.92 %) (As of 09/24/2018 09:33 AM ET)Previous Close$4.45Today's Range$4.30 - $4.322552-Week Range$4.11 - $10.74Volume2,083 shsAverage Volume16,595 shsMarket Capitalization$44.49 millionP/E Ratio-1.97Dividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York. Receive EYEN News and Ratings via Email Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:EYEN CUSIPN/A Webwww.eyenoviabio.com Phone917-289-1117 Debt Debt-to-Equity RatioN/A Current Ratio19.53 Quick Ratio19.53 Price-To-Earnings Trailing P/E Ratio-1.97 Forward P/E Ratio-2.50 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.51 per share Price / Book8.48 Profitability EPS (Most Recent Fiscal Year)($2.19) Net Income$-5,120,000.00 Net MarginsN/A Return on Equity-63.47% Return on Assets-53.91% Miscellaneous EmployeesN/A Outstanding Shares10,000,000Market Cap$44.49 million Eyenovia (NASDAQ:EYEN) Frequently Asked Questions What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." How were Eyenovia's earnings last quarter? Eyenovia Inc (NASDAQ:EYEN) issued its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.33) EPS for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.09. View Eyenovia's Earnings History. When is Eyenovia's next earnings date? Eyenovia is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Eyenovia. What price target have analysts set for EYEN? 2 analysts have issued 12-month price targets for Eyenovia's stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Eyenovia's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 536.2% from the stock's current price. View Analyst Price Targets for Eyenovia. What is the consensus analysts' recommendation for Eyenovia? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia. Who are some of Eyenovia's key competitors? Some companies that are related to Eyenovia include DURECT (DRRX), Conatus Pharmaceuticals (CNAT), REDHILL BIOPHAR/S (RDHL), BioDelivery Sciences International (BDSI), Nature's Sunshine Products (NATR), Immune Design (IMDZ), LifeVantage (LFVN), Mustang Bio (MBIO), VERONA PHARMA P/S (VRNA), Avadel Pharmaceuticals (AVDL), Sesen Bio (SESN), Eleven Biotherapeutics (EBIO), Processa Pharmaceuticals (PCSA), Syndax Pharmaceuticals (SNDX) and Tetraphase Pharmaceuticals (TTPH). Who are Eyenovia's key executives? Eyenovia's management team includes the folowing people: Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 44)Ms. Jennifer Clasby, VP of Clinical Operations (Age 64)Mr. Luke Clauson, VP of R&D (Age 39)Mr. John P. Gandolfo, CFO & Sec. (Age 57)Mr. Michael M. Rowe, VP of Marketing When did Eyenovia IPO? (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. Who are Eyenovia's major shareholders? Eyenovia's stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (2.63%) and Fairpointe Capital LLC (0.50%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Fredric N Eshelman, John P Gandolfo and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia. Which institutional investors are selling Eyenovia stock? EYEN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Eyenovia. Which institutional investors are buying Eyenovia stock? EYEN stock was purchased by a variety of institutional investors in the last quarter, including Fairpointe Capital LLC. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Fredric N Eshelman, John P Gandolfo and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia. How do I buy shares of Eyenovia? Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $4.3225. How big of a company is Eyenovia? Eyenovia has a market capitalization of $44.49 million. The company earns $-5,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. What is Eyenovia's official website? The official website for Eyenovia is http://www.eyenoviabio.com. How can I contact Eyenovia? Eyenovia's mailing address is 501 Fifth Avenue Suite 1404, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected] MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 29 (Vote Outperform)Underperform Votes: 38 (Vote Underperform)Total Votes: 67MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/24/2018 by MarketBeat.com StaffFeatured Article: Why is the ex-dividend date different from the record date?